Mad Money is a stock show on CNBC hosted by Jim Cramer - a well-known iron fist on Wall Street. He has a following of stock enthusiasts who regard his recommendations (buy or sell) as gospel. Why is he so good at what he does? He just wants to help you make money.

And to this end -- the reason I bring Cramer's passionate drive to The Diabetes Blog is simple: last week he called Novo Nordisk as a SELL. Cramer said he's beginning to worry about a backlash on drug stocks. He advised that viewers should not be greedy and should take gains in Novo Nordisk (NVO).

Perhaps the NY Times article raised some eyebrows at Big Pharma. It appears doctors are receiving handsome gifts and stipends for handing out samples of drugs that were not all that safe for most patients. The payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. In light of this blood curdling synopsis Novo got a dishonorable mention. Novo Nordisk professes to operate their company in two parts: biopharmaceuticals and Diabetes Care. The Diabetes Care segment provides insulin analogues, human insulin and insulin-related products, and oral antidiabetic drugs.

The cross examination of the C-peptide disappearing act and mysterious insulin auto-antibodies appearing where they shouldn't is just getting started. Thanks for making them sweat, Cramer!

In the next 3 to 5 years, we will have a new generation of control upon us providing continuous glucose monitoring. Some of these marvelous technologies will not require a drop of blood, while others will embody the tried-and-true stick-to-itiveness we all know and loathe.

Please join me as we browse the isles of things to come (and things now available) for continuous glucose monitoring.

The DexCom STS Continuous Glucose Monitoring System is a glucose sensor that reports glucose values every 5 minutes for up to 72 hours. The sensor is inserted in the abdomen. After a 2 hour start-up period, the STS System is calibrated with 2 fingerstick measurements taken by a traditional glucose meter. Checkout Amy Tenderich's review on Diabetes Mine of the DexCom Continuous Glucose Monitoring Sytem.

MiniMed Medtronic has 3 different versions: the Gold, the Guardian RT, and the Paradigm Real-Time Continuous Monitor.

Menarini GlucoDay S is a device worn by the patient for the continuous monitoring of glucose in the subcutaneous interstitial fluid. Monitoring is performed via insertion in the abdominal region of a microfibre for dialysis having the diameter of a human hair. Inside the microfibre a solution transports the patient's glucose to a biosensor within the instrument.

M-Biotech Glucose Biosensor is a minimally invasive implantation for painless and convenient monitoring. The key feature of our efficient Glucose Biosensor is the combination of a glucose-sensitive hydrogel and a miniature pressure sensor. Glucose-responsive hydrogels are biocompatible materials that either swell or contract when the glucose concentrations change in the body fluid surrounding the hydrogel.

The PreciSense System includes a microcapsule placement unit and a light detecting non-invasive reader unit. The microcapsule placement unit poses the right dose of glucose-responding microcapsules in the upper layer of the skin, painlessly. The glucose assay components in the microcapsules generate a fluorescence signal that corresponds to the glucose level. The non-invasive reader unit monitors this glucose binding event through FRET, Fluorescence Resonance Energy Transfer, which is directly related to the concentration of glucose.

Sensors for Medicine and Science glucose sensor is implanted under the skin in a short outpatient procedure. The sensor automatically measures interstitial glucose every few minutes, without any user intervention. The sensor implant will communicate wirelessly with a small external reader.

Synthetic Blood Implanted Glucose Biosensor claims to offer significantly more accurate glucose readings in a range of 30-500 mg/dl. The implanted Glucose Biosensor continuously monitors blood glucose without the need for finger sticks. The most accurate glucose monitor available, the implanted biosensor can be programmed to monitor blood glucose according to a predetermined schedule, thus eliminating problems of patient compliance. The sensor alarms for dangerous, life threatening conditions such as hypoglycemia.

GlucoLight Corporation is developing a low-cost non-invasive blood glucose monitor for home use by diabetic patents. GlucoLight's unique optical approach, microScatterTM (microscatter) technology, is based on patented technologies in the area of Optical Coherence Tomography (OCT) and Low Coherence Interferometry (LCI). There is a working prototype with published clinical data on healthy volunteers.

The GlucoWatch G2 Biographer was approved to detect glucose level trends and track patterns in people with diabetes. It must be used along with conventional blood glucose monitoring of blood samples. The device, which looks like a wristwatch, pulls body fluid from the skin using small electric currents. It can provide six measurements per hour for 13 hours. (See David Mendosa's review).

Diabetes is making a name for itself and it's spreading like wildfire. Politicians are uniting to build a $120 million campaign to educate diabetics to prevent the spread of the disease and its complications.

Senator Clinton criticizes the reaction to the problem, rather than taking measures to prevent it from occurring. She questions why current money is unquestionably $pent on treating complications from diabetes -- such as amputations and dialysis. Good point, Senator. Ask Bush if he's got any friends up at Eli Lilly. A good answer can always be found in a temporary restraining order. She and fellow politicians propose more money be spent on programs for weight-loss, nutrition education and other preventive efforts to best curtail the growing number of diabetics in the United States.

The legislation proposed would provide $90 million to the Centers for Disease Control and Prevention's Division of Diabetes Translation for diabetes surveillance, research and educational activities. It would also allot $30 million for three four-year projects that would examine how best to translate diet and exercise interventions into effective clinical practice.

Solianis Holding AG is a Swiss Medical device company developing a non-invasive, continuous glucose monitoring device for diabetic patients. This prototype was inspired by the realization that diabetics need a way to more effectively manage their blood glucose throughout the day, without the bloodshed. Mario Stark is revitalizing a concept in diabetes control that many have tried and few have succeeded.

The design of Solianis' non-invasive device includes monitoring as often as once a minute. Although there have been previous generations of non-invasive continuous glucose monitoring devices, they have been more adequately deemed minimally invasive. Even the Glucowatch extracted fluid from the skin, which constitutes it being minimally invasive. Perhaps the failure of true success has been due to the technology chosen not being adequate to measure glucose throughout the day in a variety of circumstances. The Solianis device is truly non-invasive. Solianis realizes the real issue is to develop a non-invasive glucose monitor that works under daily life conditions, uninterrupted. Under these conditions a lot of things happen. Factors that can affect the glucose measure include: changes in blood flow, micro-vascular circulation, sweat, the humidity and temperature fluctuations, and the thickness of the skin. All these physiological changes induce changes in the sensor that may affect the measurement of glucose. Solianis has developed a multi-sensor approach that will measure these perturbing factors and include them into the calculation of glucose for more accuracy than previous non-invasive glucose monitoring sensors.

If somebody could please bring a device like this to fruition that will accurately, continuously and conveniently measure the fluctuations in blood sugar without drawing blood - that somebody will mitigate the frustration of millions of diabetics. If that somebody happens to enjoy investing - I'd venture to say this is a potential ten bagger. A biomedical position like this in your portfolio is worth its weight in the convenience it will give diabetics. Now I'm going to sound like Jim Cramer -- I don't own the stock, but I will own the device for my charitable trust: ME!